Original ReportSafety and Efficacy of Once-Daily Hydromorphone Extended-Release Versus Twice-Daily OXYCODONE HYDROCHLORIDE (cas 124-90-3) Controlled-Release in Chinese Patients With Cancer Pain: A Phase 3, Randomized, Double-Blind, Multicenter Study

Add time:10/01/2019    Source:sciencedirect.com

Noninferiority of the efficacy of once-daily hydromorphone hydrochloride extended-release (hydromorphone ER) compared with twice-daily OXYCODONE HYDROCHLORIDE (cas 124-90-3) controlled-release (oxycodone CR) was investigated in this randomized, double-blind study in Chinese patients with moderate to severe cancer pain requiring strong oral opioid analgesics. Randomization (1:1) to hydromorphone ER (8–32 mg) or oxycodone CR (10–40 mg) was followed by dose titration (up to 8 days) and dose maintenance (28 days, weekly visits). Primary endpoint was change from baseline to end of study in “worst pain in the past 24 hours” of Brief Pain Inventory (Short Form) score on last observation carried forward (per protocol set). A total of 137 of 260 randomized patients completed maintenance phase (hydromorphone ER: n = 70; oxycodone CR: n = 67); per protocol set: 81 patients. Mean age was 53.1 years (range: 18–70 years; males: 65.3%); most common Eastern Cooperative Oncology Group performance status = 2. Least square mean difference between 2 treatment groups for primary endpoint using analysis of covariance (baseline score, covariate) was −.1 (95% confidence interval: −1.3, 1.1), with upper bound of 95% confidence interval <1.5 (predefined noninferiority margin). Most common reason for deaths was disease progression (hydromorphone ER: 6.3%; oxycodone CR: 12.7%). Treatment-emergent adverse events were comparable between treatment groups. Hydromorphone ER was noninferior to oxycodone CR in alleviating cancer pain and was well tolerated.

We also recommend Trading Suppliers and Manufacturers of OXYCODONE HYDROCHLORIDE (cas 124-90-3). Pls Click Website Link as below: cas 124-90-3 suppliers

Prev:Research reportOxycodone suppresses the apoptosis of hippocampal neurons induced by oxygen-glucose deprivation/recovery through caspase-dependent and caspase-independent pathways via κ- and δ-opioid receptors in rats
Next:Comparison between the efficacy of intralesional rituximab versus intralesional Triamcinolone (cas 124-94-7) in the treatment refractory Pemphigus Vulgaris lesions: A randomized clinical trial)